On Tuesday, Eli Lilly revealed plans to purchase Centessa Pharmaceuticals through a transaction valued at approximately $6.3 billion. The pharmaceutical giant is offering $38 in cash for each share of the Frankfurt-based biotech company.
Additionally, Lilly is providing a non-transferrable contingent value right valued at about $9 per share. Should this CVR be triggered, the acquisition’s overall value would climb to roughly $7.8 billion.
Shares of Centessa’s U.S.-traded stock experienced a dramatic 46% increase in premarket activity after the deal was made public. This spike demonstrates the significant premium Lilly is willing to pay to acquire Centessa’s sleep therapy development programs.
Centessa Pharmaceuticals plc, CNTA
The acquisition centers on treatments for sleep-wake disorders, a therapeutic area where Lilly has previously had minimal presence. Centessa offers a specialized pipeline that Lilly believes has strong commercial potential.
This represents Lilly’s second significant transaction announcement within 48 hours. One day earlier, the pharmaceutical company unveiled a $2.75 billion collaboration with Insilico Medicine focused on bringing AI-developed therapeutics to global markets.
The Insilico partnership, which leverages artificial intelligence for drug candidate identification, demonstrates Lilly’s strategy of combining conventional pharmaceutical development with cutting-edge technology platforms.
The purchase of Centessa represents a strategic expansion into sleep-wake disorder therapeutics. This category has gained increased interest from leading pharmaceutical companies in recent years.
Centessa has been advancing orexin receptor agonists, a therapeutic class that activates the brain’s wakefulness-promoting mechanisms. These compounds show promise for addressing conditions such as narcolepsy and excessive daytime sleepiness.
Lilly’s decision to offer a substantial premium indicates strong conviction in the clinical promise of these pipeline assets. The inclusion of CVR payments ensures that portion of the compensation depends on achieving specific future developmental goals.
The Insilico collaboration, unveiled on Monday, represents another facet of Lilly’s current strategic initiatives. Insilico employs artificial intelligence to generate novel drug candidates, an approach that may significantly reduce early development timelines.
Lilly announced it will license and advance therapeutics identified through Insilico’s computational platform. Complete financial details beyond the $2.75 billion principal amount remain undisclosed.
Two major deal announcements within a single 24-hour period represents an uncommon pace even for an organization of Lilly’s stature. LLY shares were trading approximately 1% higher on Tuesday morning as the market digested both transactions.
Centessa’s Frankfurt-traded shares also experienced significant upward movement following the news, as the cash proposal substantially exceeds its recent market valuation.
The post Eli Lilly (LLY) Stock Climbs on $6.3B Centessa Acquisition for Sleep Disorder Treatments appeared first on Blockonomi.
